

Christian Kowol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6372683/publications.pdf>

Version: 2024-02-01

83
papers

4,162
citations

136740

32
h-index

114278

63
g-index

84
all docs

84
docs citations

84
times ranked

5218
citing authors

#	ARTICLE	IF	CITATIONS
1	Elemental analysis: an important purity control but prone to manipulations. <i>Inorganic Chemistry Frontiers</i> , 2022, 9, 412-416.	3.0	13
2	A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. <i>Communications Chemistry</i> , 2022, 5, .	2.0	31
3	The coordination modes of (thio)semicarbazone copper(II) complexes strongly modulate the solution chemical properties and mechanism of anticancer activity. <i>Journal of Inorganic Biochemistry</i> , 2022, 231, 111786.	1.5	19
4	Albumin-targeting of an oxaliplatin-releasing platinum(IV) prodrug results in pronounced anticancer activity due to endocytotic drug uptake <i>in vivo</i> . <i>Chemical Science</i> , 2021, 12, 12587-12599.	3.7	24
5	Development of a cobalt(III)-based ponatinib prodrug system. <i>Inorganic Chemistry Frontiers</i> , 2021, 8, 2468-2485.	3.0	6
6	Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12132-12151.	2.9	34
7	Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes. <i>Dalton Transactions</i> , 2021, 50, 16053-16066.	1.6	5
8	Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism. <i>Communications Chemistry</i> , 2021, 4, .	2.0	9
9	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. <i>Inorganic Chemistry</i> , 2020, 59, 17794-17810.	1.9	11
10	Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation. <i>Dalton Transactions</i> , 2020, 49, 16887-16902.	1.6	22
11	Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13719-13732.	2.9	33
12	Improving the Stability of Maleimide-Thiol Conjugation for Drug Targeting. <i>Chemistry - A European Journal</i> , 2020, 26, 15867-15870.	1.7	29
13	High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 395-414.	2.5	28
14	Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. <i>Molecules</i> , 2020, 25, 1149.	1.7	6
15	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. <i>Bioorganic Chemistry</i> , 2020, 99, 103778.	2.0	11
16	Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. <i>International Journal of Cancer</i> , 2020, 147, 1680-1693.	2.3	16
17	Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors. <i>Proceedings (mdpi)</i> , 2019, 22, .	0.2	0
18	Zweifel an einem Dogma: Hydrolyse Äquatorialer Liganden von Pt ^{IV} -Komplexen unter physiologischen Bedingungen. <i>Angewandte Chemie</i> , 2019, 131, 7542-7547.	1.6	5

#	ARTICLE	IF	CITATIONS
19	A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt ^{IV} Complexes under Physiological Conditions. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 7464-7469.	7.2	46
20	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. <i>Inorganic Chemistry</i> , 2019, 58, 16676-16688.	1.9	13
21	Synthesis, Characterization and <i>in vitro</i> Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. <i>Chemistry and Biodiversity</i> , 2019, 16, e1800520.	1.0	9
22	Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2019, 190, 85-97.	1.5	32
23	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
24	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1062-1082.	2.5	137
25	Comparison of metabolic pathways of different $\hat{1}\pm$ -N-heterocyclic thiosemicarbazones. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2343-2361.	1.9	12
26	Structure elucidation and quantification of the reduction products of anticancer Pt(^{iv}) prodrugs by electrochemistry/mass spectrometry (EC-MS). <i>Analyst</i> , The, 2018, 143, 1997-2001.	1.7	6
27	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. <i>Oncolimmunology</i> , 2018, 7, e1424676.	2.1	35
28	Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 154, 321-331.	1.4	20
29	A comparative study of $\hat{1}\pm$ -N-pyridyl thiosemicarbazones: Spectroscopic properties, solution stability and copper(II) complexation. <i>Inorganica Chimica Acta</i> , 2018, 472, 264-275.	1.2	22
30	Complexes of pyridoxal thiosemicarbazones formed with vanadium(IV) and copper(II): Solution equilibrium and structure. <i>Inorganica Chimica Acta</i> , 2018, 472, 243-253.	1.2	17
31	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. <i>Cells</i> , 2018, 7, 259.	1.8	8
32	The thiosemicarbazone Me ₂ NNMe ₂ induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. <i>Cell Death and Disease</i> , 2018, 9, 1052.	2.7	38
33	Critical assessment of different methods for quantitative measurement of metallodrug-protein associations. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7211-7220.	1.9	17
34	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2632-2643.	1.7	22
35	EGFR-targeting peptide-coupled platinum(IV) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 591-603.	1.1	23
36	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity <i>in vivo</i> . <i>Chemical Science</i> , 2017, 8, 2241-2250.	3.7	114

#	ARTICLE	IF	CITATIONS
37	Multifunctional \pm \hat{I}^2 \hat{I}^2 Integrin-Specific Peptide \hat{I}^2 Pt(IV) Conjugates for Cancer Cell Targeting. <i>Bioconjugate Chemistry</i> , 2017, 28, 2429-2439.	1.8	18
38	Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS. <i>Analyst</i> , 2017, 142, 3165-3176.	1.7	18
39	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 122.	3.5	33
40	Another step toward DNA selective targeting: Ni ^{II} and Cu ^{II} complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes. <i>Dalton Transactions</i> , 2016, 45, 7758-7767.	1.6	49
41	Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs. <i>ChemMedChem</i> , 2016, 11, 2410-2421.	1.6	18
42	Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity. <i>RSC Advances</i> , 2016, 6, 55848-55859.	1.7	11
43	Impact of Stepwise NH ₂ -Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6739-6752.	2.9	42
44	Multi-scale imaging of anticancer platinum(^{IV}) compounds in murine tumor and kidney. <i>Chemical Science</i> , 2016, 7, 3052-3061.	3.7	36
45	Differences in protein binding and excretion of Triapine and its Fe(III) complex. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 61-69.	1.5	20
46	Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. <i>Oncotarget</i> , 2016, 7, 84556-84574.	0.8	15
47	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. <i>Cancer Letters</i> , 2015, 361, 112-120.	3.2	24
48	Vanadium(IV) complexes of Triapine and related thiosemicarbazones: Synthesis, solution equilibrium and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2015, 152, 62-73.	1.5	20
49	<i>Metal Drugs</i> , 2015, , 2782-2785.		0
50	<i>Metal Drugs</i> , 2015, , 1-4.		0
51	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2436-2449.	1.9	25
52	Enhanced Anticancer Activity and Circumvention of Resistance Mechanisms by Novel Polymeric/Phospholipidic Nanocarriers of Doxorubicin. <i>Journal of Biomedical Nanotechnology</i> , 2014, 10, 1369-1381.	0.5	21
53	Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 12930-12935.	7.2	55
54	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. <i>Molecular Pharmacology</i> , 2014, 85, 451-459.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Transactions, 2014, 43, 1096-1104.	1.6	35
56	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science, 2014, 5, 2925-2932.	3.7	552
57	Tumorspezifische, Hypoxie-abhängige Aktivierung von EGFR-Inhibitoren. Angewandte Chemie, 2014, 126, 13144-13149.	1.6	8
58	Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019. Journal of Biomedical Nanotechnology, 2014, 10, 877-884.	0.5	36
59	Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	2.2	84
60	Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair. Molecular Cancer Therapeutics, 2013, 12, 1073-1084.	1.9	46
61	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	2.9	34
62	Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. Dalton Transactions, 2012, 41, 14404-14415.	1.6	76
63	Complex Formation Ability of Salicylaldehyde Thiosemicarbazone towards Zn ^{II} , Cu ^{II} , Fe ^{II} , Fe ^{III} and Ga ^{III} Ions. European Journal of Inorganic Chemistry, 2012, 2012, 4036-4047.	1.0	44
64	Impact of terminal dimethylation on the resistance profile of 1-N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	2.0	16
65	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 409-423.	1.1	120
66	Interaction of Triapine and related thiosemicarbazones with iron(III)/iron(II) and gallium(III): a comparative solution equilibrium study. Dalton Transactions, 2011, 40, 5895.	1.6	65
67	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants and Redox Signaling, 2011, 15, 1085-1127.	2.5	420
68	Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde) Tj ETQq0 0 0 rgBT /Overlock 10 Biochemistry, 2011, 105, 1422-1431.	1.5	105
69	Hydroxy and ether functionalized dithiolanes: Models for the active site of the [FeFe] hydrogenase. Journal of Organometallic Chemistry, 2011, 696, 1084-1088.	0.8	14
70	A quantitative structure-activity approach for lipophilicity estimation of antitumor complexes of different metals using microemulsion electrokinetic chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 409-413.	1.4	17
71	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. Journal of Inorganic Biochemistry, 2011, 105, 46-51.	1.5	107
72	Comparative Solution Equilibrium Study of the Interactions of Copper(II), Iron(II) and Zinc(II) with Triapine (3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone) and Related Ligands. European Journal of Inorganic Chemistry, 2010, 2010, 1717-1728.	1.0	74

#	ARTICLE	IF	CITATIONS
73	Synthetic and Electrochemical Studies of [2Fe2S] Complexes Containing a 4-aminopyridine-2-thiolane-4-carboxylic Acid Moiety. <i>European Journal of Inorganic Chemistry</i> , 2010, 2010, 5079-5086.	1.0	9
74	Fluorescence properties and cellular distribution of the investigational anticancer drug Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(ii) complex. <i>Dalton Transactions</i> , 2010, 39, 704-706.	1.6	77
75	Investigation of amino acid containing [FeFe] hydrogenase models concerning pendant base effects. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1236-1244.	1.5	18
76	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5032-5043.	2.9	143
77	An Electrochemical Study of Antineoplastic Gallium, Iron and Ruthenium Complexes with Redox Noninnocent 1-N-Heterocyclic Chalcogensemicarbazones. <i>Inorganic Chemistry</i> , 2008, 47, 11032-11047.	1.9	57
78	Synthesis and Reactivity of the Aquation Product of the Antitumor Complex $trans-[Ru^{III}Cl_4(indazole)_2]^{+}$. <i>Inorganic Chemistry</i> , 2008, 47, 6513-6523.	1.9	50
79	Gallium(III) and Iron(III) Complexes of 1-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1254-1265.	2.9	145
80	Ruthenium(II) Complexes of Thiosemicarbazones: The First Water-Soluble Complex with pH-Dependent Antiproliferative Activity. <i>European Journal of Inorganic Chemistry</i> , 2007, 2007, 2870-2878.	1.0	43
81	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. <i>Journal of Inorganic Biochemistry</i> , 2007, 101, 1946-1957.	1.5	71
82	The First Metal-Based Paullone Derivative with High Antiproliferative Activity in Vitro. <i>Inorganic Chemistry</i> , 2006, 45, 1945-1950.	1.9	46
83	Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteins. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1819-1826.	1.5	100